UCB (EBR:UCB) UCB Media Room: Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY®▼ (romosozumab) can help to close the treatment gap in osteoporosi

Transparency directive : regulatory news

12/04/2024 18:01

https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3D0szJ_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0RGpSKVTD9VAA8lRXBRm-2FGqCNjzFFZaj= j8EYMA4XO0WMlWqaxWTCc110OcbG0GavzybXxq-2B8DfZHSRmyWZNKbVmbHXNauYogWluZvM7Xk= hb9WTZJIoQJmrAEJYJDu0FRg6EmRaPPtjpmP2IFuaSm9BrsZomI1LyTuMqQZDaSaHLNvx-2Bi4R= S7vJuHHoLv0KlcKf3-2BEfOx5C8cCp8LcQ-3D ** Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENI= TY^=C2=AE=E2=96=BC (romosozumab) can help to close the treatment gap in ost= eoporosi ------------------------------------------------------------ =C2=B7 The first cohort patient study in Denmark for romosozumab highlights= its use in routine clinical practice. =C2=B7 Patients within the romosozumab cohort group had a fracture history = in the past three years which included hip and spine fractures prior to tre= atment with romosozumab.^1=C2=A0 =C2=B7 The study observations can help to inform optimal clinical use of ro= mosozumab for postmenopausal women at high risk of fracture. =E2=96=BC This medicinal product is subject to additional monitoring. This = will allow quick identification of new safety information. Healthcare profe= ssionals are asked to report any suspected adverse reactions. Brussels (Belgium), 12 April 2024 =E2=80=93 UCB, a global biopharmaceutical= company, today announced key findings from the first retrospective patient= cohort study in Denmark to observe the characteristics of patients selecte= d for romosozumab treatment in routine clinical practice. The data were pre= sented as a poster presentation at the World Congress on Osteoporosis, Oste= oarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2024 in London, UK,= 11-14 April. The observational, retrospective cohort study included female patients aged= 50 years or older receiving osteoporosis medication during September 2020 = to October 2023, identified by prescription and hospital registry data. Ove= rall, 149,395 patients were included in the analysis; of these, 622 with a = fracture in the three years before the date of cohort entry were treated wi= th romsozumab.^1=C2=A0 The study observed that, of patients who had sustained a fracture at any sk= eletal site in the three years before the date of cohort entry and were tre= ated with romosozumab, fracture history included hip fractures (n=3D79/N=3D= 622 (12.7%)) and spine fractures (n=3D64/N=3D622 (10.3%)), in addition to n= on-hip, non-spine (n=3D303/N=3D622 (48.7%)) and osteoporosis with pathologi= cal fracture not related to malignancy or other bone diseases (n=3D335/N=3D= 622 (53.9%)). The study also highlighted that of the 622 female patients tr= eated with romosozumab, 44.5% (n=3D277) had not received any prior treatmen= t for osteoporosis.^1=C2=A0 =E2=80=9CIt is vital that patients with osteoporosis at high risk of fractu= re receive timely and appropriate care from the offset to reduce the risk o= f future fractures and improve outcomes,=E2=80=9D said lead study investiga= tor Prof Bente Langdahl (Clinical Professor, Aarhus University Hospital, De= nmark). =E2=80=9CBy offering critical insights into the treatment patterns = of romosozumab and other osteoporosis treatments in a real-world setting, t= his study allows us to further investigate prescription patterns and the pr= ofile of patients who may benefit the most from the use of romosozumab as a= first-line treatment. This knowledge will help us improve treatment of pat= ients with severe osteoporosis at high risk of fracture." The global impact of osteoporosis is profound, with one in three women over= the age of 50 likely to experience a fracture caused by osteoporosis.^2 In= Europe alone, the economic cost is estimated at 37.5 billion EUR =E2=80=93= a number predicted to increase by 27% by 2030.^3 Despite this, data in Eur= ope has demonstrated that up to 85% of women are not treated for underlying= osteoporosis following a fragility fracture.^4 =C2=A0 =E2=80=9CThis cohort patient study provides an invaluable blueprint to info= rm future treatment decision-making and support optimal use of romosozumab = in clinical practice, both in Denmark and across Europe,=E2=80=9D said Emma= nuel Caeymaex, Executive Vice President, Immunology and U.S. Solutions at U= CB. =E2=80=9CThe study findings enable us to understand the use of romosozu= mab as a treatment option in the real world and demonstrate its potential i= n closing the treatment gap for patients at high risk of fracture.=E2=80=9D Romosozumab was approved in the European Union in December 2019 for the tre= atment of severe osteoporosis in postmenopausal women at high risk of fract= ure.^5=C2=A0 WCO - World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Di= seases; IOF - International Osteoporosis Foundation, ESCEO - European Socie= ty for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. For further information, contact UCB:=C2=A0 Investor Relations Antje Witte T +32 2 559 9414 Antje.witte@ucb.com =C2=A0 Global Communications Adriaan Snauwaert T+32 497 70 23 46 Adriaan.snauwaert@ucb.com Date of preparation: April 2024 | GL-RM-2400001 =C2=A9 UCB Biopharma SRL, 2024. All rights reserved. About the European retrospective cohort study A retrospective cohort study was conducted using data recorded from Danish = administrative registries. The study population comprised female patients a= ged =E2=89=A550 receiving osteoporosis medication during the period from Se= ptember 2020 to October 2023. The objective of the study is to observe patt= erns and influencing factors of romosozumab use in routine clinical practic= e in Denmark. The study included three cohorts: i) patients with severe ost= eoporosis treated with romosozumab, ii) patients with severe osteoporosis n= ot treated with romosozumab, and iii) patients who did not have severe oste= oporosis and were not treated with romosozumab. Patients were considered as= having severe osteoporosis if they had sustained a fracture at any skeleta= l site in the three years before the index date (BMD data were not availabl= e in the dataset). The characteristics investigated in the three cohorts in= cluded: age, index treatment, comorbidities, osteoporosis treatment history= , dispensing of drugs that increase risk of falling and fracture, fracture = history, and use of glucocorticoids.=C2=A0 About EVENITY^=C2=AE (romosozumab) Romosozumab is a bone-forming monoclonal antibody. It is designed to work b= y inhibiting the activity of sclerostin, which simultaneously results in in= creased bone formation and to a lesser extent decreased bone resorption. Th= e romosozumab development program includes 19 clinical studies that enrolle= d approximately 14,000 patients. EVENITY has been studied for its potential= to reduce the risk of fractures in an extensive global phase 3 program tha= t included two large fracture trials comparing romosozumab to either placeb= o or active comparator in over 11,000 postmenopausal women with osteoporosi= s. Amgen and UCB are co-developing romosozumab. Important Safety Information about EVENITY^=C2=AE (romosozumab) in the EU/E= EA In the EU, romosozumab is indicated for treatment of severe osteoporosis in= postmenopausal women at high risk of fracture.=C2=A0 Contraindications: Romosozumab is contraindicated in patients who are aller= gic to romosozumab or any of the excipients, who have low levels of calcium= in the blood (hypocalcaemia), or who have a history of myocardial infarcti= on (heart attack) or stroke. Myocardial infarction or stroke: Heart attack = and stroke have been reported in patients receiving romosozumab in randomis= ed controlled trials (uncommon). Treatment with romosozumab should not be i= nitiated in patients with a history of heart attack or stroke. When determi= ning whether to use romosozumab for an individual patient, the presence of = risk factors for cardiovascular problems, including established cardiovascu= lar disease, high blood pressure, high blood fat levels, diabetes, smoking = or kidney problems, should be evaluated. romosozumab should only be used if= the prescriber and patient agree that the benefit outweighs the risk. If a= patient experiences a myocardial infarction or stroke during therapy, trea= tment with romosozumab should be discontinued. Hypocalcaemia: Transient hyp= ocalcaemia has been observed in patients receiving romosozumab. Hypocalcaem= ia should be corrected prior to initiating therapy with romosozumab and pat= ients should be monitored for signs and symptoms of hypocalcaemia. If any p= atient presents with suspected symptoms of hypocalcaemia during treatment, = calcium levels should be measured. Patients should be adequately supplement= ed with calcium and vitamin D. Patients with severe renal impairment (estim= ated glomerular filtration rate [eGFR] 15 to 29ml/min/1.73m2) or receiving = dialysis are at greater risk of developing hypocalcaemia and the safety dat= a for these patients are limited. Calcium levels should be monitored in the= se patients. Hypersensitivity: Clinically significant hypersensitivity reac= tions, including angioedema, erythema multiforme, and urticaria occurred in= the romosozumab group in clinical trials. If an anaphylactic or other clin= ically significant allergic reaction occurs, appropriate therapy should be = initiated and use of romosozumab should be discontinued. Osteonecrosis of t= he Jaw: Osteonecrosis of the jaw (ONJ) has been reported rarely in patients= receiving romosozumab. The following risk factors should be considered whe= n evaluating a patient=E2=80=99s risk of developing ONJ: (1) potency of the= medicinal product that inhibits bone resorption (the risk increases with t= he antiresorptive potency of the compound), and cumulative dose of bone res= orption therapy, (2) cancer, co-morbid conditions (e.g. anaemia, coagulopat= hies, infection), smoking, (3) concomitant therapies: corticosteroids, chem= otherapy, angiogenesis inhibitors, radiotherapy to head and neck, (4) poor = oral hygiene, periodontal disease, poorly fitting dentures, history of dent= al disease, invasive dental procedures e.g. tooth extractions. All patients= should be encouraged to maintain good oral hygiene and receive routine den= tal check-ups. Dentures should fit correctly. Patients under dental treatme= nt, or who will undergo dental surgery (e.g. tooth extractions) whilst bein= g treated with romosozumab should inform their doctor about their dental tr= eatment and inform their dentist that they are receiving romosozumab. Patie= nts should immediately report any oral symptoms such as dental mobility, pa= in or swelling or non-healing of sores or pus discharge during treatment wi= th romosozumab. Patients who are suspected of having or who develop ONJ whi= le receiving romosozumab should receive care by a dentist or an oral surgeo= n with expertise in ONJ. Discontinuation of romosozumab therapy should be c= onsidered until the condition resolves and contributing risk factors are mi= tigated where possible. Atypical Femoral Fractures: Atypical low-energy or = low trauma fracture of the femoral shaft, which can occur spontaneously, ha= s been reported rarely in patients receiving romosozumab. Any patient who p= resents with new or unusual thigh, hip, or groin pain should be suspected o= f having an atypical fracture and should be evaluated to rule out an incomp= lete femur fracture. Patient presenting with an atypical femur fracture sho= uld also be assessed for symptoms and signs of fracture in the contralatera= l limb. Interruption of romosozumab therapy should be considered, based on = an individual benefit-risk assessment. Adverse Reactions: The most common a= dverse reactions were nasopharyngitis (13.6%) and arthralgia (12.4%). Commo= n adverse reactions included hypersensitivity, sinusitis, rash, dermatitis,= headache, neck pain, muscle spasms and injection site reactions (most freq= uent injection site reactions were pain and erythema). Uncommon adverse rea= ctions were urticaria, hypocalcaemia, stroke, myocardial infarction and cat= aract. Finally, rare side effects were serious allergic reactions which cau= sed swelling of the face, throat, hands, feet, ankles or lower legs (angioe= dema) and acute skin eruption (erythema multiforme). Refer to the European Summary of Product Characteristics for other adverse = reactions and full prescribing information. Available at https://u7061146.c= t.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC2tJ60H3Fdk1VajTAI= Aj7NPJeYj-2Ba-2BL1r-2B0jLM-2FtfvSeD3KLQsazq58-2BxwfyV7LSQXCAZgUBKLrMCFWyh3w= kMDER6dL987KEnvEiIbPpRtyXKjpJpxWvR2Z4HLzK3wzcZg-3D-3DlYTU_2dCLUNbuBjhX746-2= FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3= MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0R= GpSKVTD9VAA8lRXBRm-2FGqCNjzFFZajj8EYMA4XO0WMlWqaxWTCc110OcbG71qCFAhd96SR9BT= q0dgJ8Nh8GtHYFkiYxEhnHk0OuUKR9spZ2c9c4nurZw9ermXw8DXCvRxF-2BgqYbaTuwXHvaMVM= 7-2BkpvWYo-2BRJlSsqhbkR4mo1BKrhMIj1vtqIjtZeUFM4QzZnDZFrPBh-2FB5HU5ME-3D EVENITY^=C2=AE is a registered trademark of the UCB Group of Companies.=C2= =A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 8,000 people op= erating in more than 40 countries, the company generated revenue of =E2=82= =AC5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). F= ollow us on Twitter: @UCB_news About the Amgen and UCB Collaboration Since 2004, Amgen and UCB have been working together under a collaboration = and license agreement to research, develop and market antibody products tar= geting the protein sclerostin. As part of this agreement, the two companies= continue to collaborate on the development of romosozumab for the treatmen= t of osteoporosis. This gene-to-drug project demonstrates how Amgen and UCB= are joining forces to translate a genetic discovery into a new medicine, t= urning conceptual science into a reality. Forward looking statements=C2=A0 This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 UCB is providing this information as of the date of this press release and = expressly disclaims any duty to update any information contained in this pr= ess release, either to confirm the actual results or to report a change in = its expectations. There is no guarantee that new product candidates in the = pipeline will progress to product approval or that new indications for exis= ting products will be developed and approved. Products or potential product= s which are the subject of partnerships, joint ventures or licensing collab= orations may be subject to differences between the partners. Also, UCB or o= thers could discover safety, side effects or manufacturing problems with it= s products after they are marketed. Moreover, sales may be impacted by inte= rnational and domestic trends toward managed care and health care cost cont= ainment and the reimbursement policies imposed by third-party payers as wel= l as legislation affecting biopharmaceutical pricing and reimbursement. References 1. Langdahl B, Lorentzon M, Borgen TT, Alstad C, Bajtner E, Rieem Dun A, Ka= arill T, Konradsen M, Tsitlakidis E, Moayyeri A. Romosozumab in Denmark =E2= =80=93 A registry study on osteoporosis patients. Abstract presented at the= World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease= s 2024, London (11th =E2=80=93 14th April, 2024). 2. S=C3=B6zen T, =C3=96z=C4=B1=C5=9F=C4=B1k L, Ba=C5=9Faran N=C3=87. An ove= rview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46=E2=80= =9356. 3. IOF. Burden of Osteoporosis. [Online] Available at: https://u7061146.ct.= sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyxclTDEAHMhn9svyzYA= z3SthNjteviRsQ7P-2BEnN15sg2PaTCRCq-2B6QG24nYIcpgCdKFnR8DIFXVLlmx-2B-2BId5g8= -3DRlCt_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ= 0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33-2BW= lRP9gZHuN0zxNyx8Fa7M9Le0RGpSKVTD9VAA8lRXBRm-2FGqCNjzFFZajj8EYMA4XO0WMlWqaxW= TCc110OcbG8mROYda8-2FfN3HG-2FF8EgMTTLMw1MNnCCcuGDvv0oZTz1aWwCQGdOjBlXPfTtWO= rXXmBNkpmTH1dzPNFuIRI-2BEp-2FPK3fvncRjC7Gp7Aen5BLE40AnapQRGvaXx55y-2B2YYcSp= uBamBCK-2FXy7PsdymVwiM-3D (Accessed February 2024). 4. BROKEN BONES, BROKEN LIVES: A roadmap to solve the fragility fracture cr= isis in Europe. (n.d.). The International Osteoporosis Foundation (IOF), [O= nline] Available at: https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.g= qh-2BaxUzlo7XKIuSly0rCyxclTDEAHMhn9svyzYAz3SxLmZf58KQ8ers8GovkiDuXn09GkjkYf= SCZ0NTobKhJ9i6hbvsSpZXRuim4180zmzkiNzYP-2FLHf7d63EOjCYfu8JYO7VYfewJfMX4wyQD= w4MxnqAb31U9FOPXNtKxiIJd-2FQQhIavuJG9ZzFMwi7-2Bx4WdPj_2dCLUNbuBjhX746-2FvM6= 3L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQ= eFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0RGpSK= VTD9VAA8lRXBRm-2FGqCNjzFFZajj8EYMA4XO0WMlWqaxWTCc110OcbG8-2FrUC7Sz34ZuQp4Cj= mY-2BBaUNe0ZIadrXAPfVMMQw79-2BamsVEji9gjoNXu03InRi6SbzQYPgjMjLQWfarK1Kkj2EE= atw5j0CAonfBgezK1bxIjuilUa0vwzIvUqKjGAbDdN1Kyr7SjzzFZUzc7XhVRM-3D (https://= u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rCyxclTDE= AHMhn9svyzYAz3SxLmZf58KQ8ers8GovkiDuXn09GkjkYfSCZ0NTobKhJ9i6hbvsSpZXRuim418= 0zmyqkOW40FEsYy7QT0OPM-2BrO9BPW_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZ= gmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkE= ZvEGLNn-2B6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0RGpSKVTD9VAA8lRXBRm-2FGqCNj= zFFZajj8EYMA4XO0WMlWqaxWTCc110OcbG3lFLcYgcLYR1zuS5sj53khfFQrgiyFdZZ0W8SrKdO= kowZd55Ez56KQF3oILcS-2Bjq0feWnQ4KuGa3T0w2B257H6OJpflC-2F6-2BtekAIk3KwbkCn-2= FejlQf37rFPwgNrCZ1C-2B9zeQg6mFDaPZF-2BR08h34SU-3D 2018_EU6_Report_BrokenBon= esBrokenLives_English.pdf) . (Accessed February 2024).=C2=A0 5. EVENITY^=C2=AE EU SmPC. Available at https://u7061146.ct.sendgrid.net/ls= /click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC2tJ60H3Fdk1VajTAIAj7NPJeYj-2Ba-2BL= 1r-2B0jLM-2FtfvSeD3KLQsazq58-2BxwfyV7LSQXCAZgUBKLrMCFWyh3wkMDER6dL987KEnvEi= IbPpRtyXKjpJpxWvR2Z4HLzK3wzcZg-3D-3DCJbn_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM= -2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8c= V3s33SbkEZvEGLNn-2B6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0RGpSKVTD9VAA8lRXBR= m-2FGqCNjzFFZajj8EYMA4XO0WMlWqaxWTCc110OcbG2e-2BJymE99VAilZCjkPXMkJFu2cv4D3= OOzayH25bWdnW-2F8Bq8krtADdu7m9GkbGVEUE0-2FzNzpssEEwotOVSGITrBV2dRqX5OeUnEK5= tGcLtfcIoqRsHqNTL94i-2BYNg1EuD2jf3evAuZusjN0weHfSvc-3D (Accessed February 2= 024).=C2=A0 GenericFile UCB PR WCO ENG April 12 2024 (https://u7061146.ct.sendgrid.net/ls/click?upn= =3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbtZNcDtG8Y2MhOGwqLBpz= bE1wNqeE3EPQTb2Cra2PLtr8VRx56sxs7rHU6USDZ-2FBc-3DkIEF_2dCLUNbuBjhX746-2FvM6= 3L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQ= eFO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0RGpSK= VTD9VAA8lRXBRm-2FGqCNjzFFZajj8EYMA4XO0WMlWqaxWTCc110OcbG0LJ8XvWlg7xo0S7YTzC= SJB7K5Gfz8T4kwv2As8ZyxGJpCcMwOUf7roCovl0EdR-2Bcwewt9Ck3WfFNavZuz5d2n7VG7zeL= Nan8tqnRFacgB1O-2BTUqyzNZ3DUcPfYyPd6GDv4PLlcPwXgjQnvaqyoQ0PE-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUN3-2BPRGDhI9gLtHW4HNQXPsC= HUsvT8RuujC-2BrGa4CASvr7JVgL012dmzUEzhT904rPJsEuFpDQLrZ2pTNz-2Fg5oyJfFojqlv= RkUV3i80d9mwDo-3DAdnn_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1= Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B= 6FohpNoV33-2BWlRP9gZHuN0zxNyx8Fa7M9Le0RGpSKVTD9VAA8lRXBRm-2FGqCNjzFFZajj8EY= MA4XO0WMlWqaxWTCc110OcbG6MycfZxeI1ic-2B8j40g3EeYrrHe8xHWJBt8MRofQ0yb15awFvo= wotfsdb2rhmgcRwp1jMXZM-2Fl7Bhq66Nx1VaqJu6xTLlfbeKskPzXeNdN7ja5OuxbPkgguhhys= UBHrl-2B7tPm4lX4LUKHnLFIrgdlmo-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

source : webdisclosure.com

UCB's latest news

26/04/2024 20:00

UCB (EBR:UCB) UCB Media Room: Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY®▼ (romosozumab) can help to close the treatment gap in osteoporosi

Transparency directive : regulatory news

UCB's latest news

Other stories